Weekly Report
·
BioHedge Weekly
13D/13G filings from 18 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform — clinical trials, SEC filings, and hedge fund positioning, linked by company.
4
Filings
4
Activist (13D)
0
New Positions
4
Companies
Weekly Filing Volume
13D (Activist)
13G (Passive)
This week
Filings This Week
| Company | Fund | Ownership | Type |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | RA Capital Management | 21.2% ↓1.2 | 13D/A [SEC] |
| PMV Pharmaceuticals, Inc. (PMVP) | OrbiMed | 0.0% | 13D/A [SEC] |
| Bicara Therapeutics (BCAX) | RA Capital Management | 11.5% | 13D/A [SEC] |
| Larimar Therapeutics, Inc. (LRMR) | Deerfield Management | 34.4% ↓1.4 | 13D/A [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses >5% ownership in a company for the first time.
We track 18 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.